In:
Blood, American Society of Hematology, Vol. 122, No. 12 ( 2013-09-19), p. 2135-2141
Abstract:
UCBT is a suitable option for children with JMML, being able to cure a relevant proportion of patients. Because disease recurrence remains the major cause of treatment failure after UCBT, strategies aimed at reducing relapse are desirable.
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2013-03-491589
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2013
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7
Permalink